Eli Lilly and Company (NYSE:LLY) Shares Purchased by Hart & Patterson Financial Group LLC

Hart & Patterson Financial Group LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 18.1% during the third quarter, Holdings Channel.com reports. The firm owned 802 shares of the company’s stock after purchasing an additional 123 shares during the quarter. Hart & Patterson Financial Group LLC’s holdings in Eli Lilly and Company were worth $711,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Able Wealth Management LLC purchased a new stake in Eli Lilly and Company during the fourth quarter worth approximately $75,000. Raleigh Capital Management Inc. boosted its holdings in shares of Eli Lilly and Company by 241.9% in the 4th quarter. Raleigh Capital Management Inc. now owns 506 shares of the company’s stock valued at $295,000 after buying an additional 358 shares in the last quarter. Sierra Summit Advisors LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $3,726,000. Integrated Advisors Network LLC raised its stake in Eli Lilly and Company by 2.3% during the 4th quarter. Integrated Advisors Network LLC now owns 11,780 shares of the company’s stock worth $6,867,000 after acquiring an additional 270 shares in the last quarter. Finally, Centaurus Financial Inc. lifted its position in Eli Lilly and Company by 1.8% in the fourth quarter. Centaurus Financial Inc. now owns 2,003 shares of the company’s stock valued at $1,167,000 after acquiring an additional 35 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $932.06 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The stock has a 50 day simple moving average of $910.84 and a 200-day simple moving average of $852.86. The company has a market cap of $885.83 billion, a price-to-earnings ratio of 137.27, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, equities analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Bank of America raised their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a report on Friday, August 9th. BMO Capital Markets boosted their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Citigroup initiated coverage on shares of Eli Lilly and Company in a research report on Friday, September 13th. They set a “buy” rating and a $1,060.00 target price on the stock. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Finally, Berenberg Bank raised their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $979.29.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.